Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Trends Cardiovasc Med. 2018 Apr;28(3):200-209. doi: 10.1016/j.tcm.2017.08.008. Epub 2017 Aug 18.
Mitral valve regurgitation (MR) affects approximately 4 million people in the United States alone, increasing in prevalence with age. Approved by the Food and Drug Administration (FDA) in October 2013, percutaneous edge-to-edge transcatheter mitral valve repair (also known as the MitraClip system) has been used in over 40,000 patients globally. Additionally, there is keen interest and early exploration into the use of MitraClip for treatment of severe symptomatic tricuspid regurgitation, another undertreated disease with significant morbidity and mortality. In this manuscript, we aim to review the current indications, procedural details as well as emerging indications for this novel technology.
二尖瓣反流（MR）在美国就影响着大约 400 万人，且其发病率随年龄增长而增加。经食品和药物管理局（FDA）于 2013 年 10 月批准，经皮缘对缘经导管二尖瓣修复术（也称为 MitraClip 系统）已在全球超过 40000 例患者中使用。此外，人们对使用 MitraClip 治疗严重症状性三尖瓣反流也非常感兴趣，并进行了早期探索，因为三尖瓣反流是另一种治疗不足的疾病，具有显著的发病率和死亡率。在本手稿中，我们旨在回顾这项新技术的当前适应证、操作细节和新的适应证。
